DF/HCC Pipelines in Oncology: Genelux
Thursday, May 15 at 12:30pm to 2:00pm
DF/HCC is hosting a Pipelines in Oncology Seminar with Genelux Corporation on Thursday, May 15, 2014 from 12:30 - 2:00 pm in Smith 308/309 at the Dana-Farber Cancer Institute. Genelux has developed an oncolytic-virus based technology platform, and a wide variety of payloads that are tools for cancer detection and therapy. Late phase I studies are promising, and are being conducted at Royal Marsden Hospital in London, Memorial Sloan Kettering Hospital in New York, UCSD Hospital in San Diego and University of Leeds Hospital in West Yorkshire, England. They are also working to develop a cancer vaccine.
Genelux Founder and CEO Dr. Aladar Szalay will be meeting with investigators at MGH in the morning and DFCI in the afternoon. If you are interested in a small group or 1:1 meeting with Dr. Szalay, please write to Andrea Talis (MGH), or Deborah Goff (DFCI).
About Genelux Corporation
Lunch will be provided at DFCI for the seminar. Please register for the seminar at http://events.dfhcc.harvard.edu/events/58
No recent activity